Loading...
Images of Yohann Loriot
(0 from 0 )1
0
0
News
De-escalation chemotherapy after negative PET scan appears safe ...www.healio.com › news › hematology-oncology › deescalation-chemother...
www.healio.com
24-Feb · “A negative FDG-[PET] predicts the absence of viable seminoma cells after chemotherapy in men with metastatic seminoma,” Yohann Loriot, MD, ...
History of Changes for Study: NCT ClinicalTrials.govclinicaltrials.gov › history › NCT
clinicaltrials.gov
Villejuif, France, Contact:Contact: Yohann LORIOT, MD Contact:Principal Investigator: Yohann LORIOT, MD ...
Addition of ramucirumab to docetaxel extends PFS in advanced ...
www.healio.com
... first-line therapy and those with platinum-resistant metastatic urothelial cancer, docetaxel and ramucirumab may be given. Yohann Loriot, MD ...
Complete Response to Atezolizumab in UC Appears Durable - Renal ...
www.renalandurologynews.com
Yohann Loriot, MD, of Institut de Cancérologie Gustave Roussy in Villejuif, France, and colleagues looked at 3 small cohorts of patients with ...
Physicians & MDs
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinomawww.nejm.org › doi › full › nejmoa
www.nejm.org
25-Jul · Yohann Loriot, M.D.,; Andrea Necchi, M.D.,; Se Hoon Park, M.D.,; Jesus Garcia-Donas, M.D.,; Robert Huddart, M.C.R.P.,; Earle Burgess, M.D., ...
[PPT] Download Figures (PPT) - The Lancetwww.thelancet.com › lanonc › article › PIIS (21)
www.thelancet.com
... Sydney Akapame, PhD, Ademi E Santiago-Walker, PhD, Manish Monga, MD, Anne O'Hagan, MPH, Yohann Loriot, MD Andrea Necchi, Yohann Loriot, Se Hoon Park, ...
Network Profiles
LinkedIn: Yohann Loriot - Médecin - Institut Gustave Roussy | LinkedIn
View Yohann Loriot's profile on LinkedIn, the world's largest professional community. Yohann has 1 job listed on their profile. See the complete profile on ...
LinkedIn: Yohann Loriot | LinkedIn
Voir le profil professionnel de Yohann Loriot sur LinkedIn. Grâce à LinkedIn, le plus grand réseau professionnel au monde, les professionnels comme Yohann ...
Yohann Loriot, PhD, MD | ASCO - American Society of Clinical ...www.asco.org › people › yohann-loriot-md-phd
www.asco.org
Yohann Loriot, PhD, MD. Connect with Us. Facebook Twitter LinkedIn YouTube. Footer 1. About ASCO · Contact Us · Licensing · ASCO Store. Footer 2.
Interests
Seminoma: Risk-Adapted Strategy Could Mean Less Medscapewww.medscape.com › viewarticle
www.medscape.com
24-Feb · ... noted lead investigator Yohann Loriot, MD, PhD, a medical oncologist at Gustave Roussy Institute, Villejuif, France.
New drug 'retrains' immune system to fight ag | EurekAlert!
www.eurekalert.org
... MD, at the Icahn School of Medicine at Mount Sinai in New York; Yohann Loriot, MD, MSc, at the Institute Gustave Roussy in Villejuif, France; ...
Treatment breakthrough for advanced bladder cancer -- ScienceDaily
www.sciencedaily.com
Thomas Powles, Joseph Paul Eder, Gregg D. Fine, Fadi S. Braiteh, Yohann Loriot, Cristina Cruz, Joaquim Bellmunt, Howard A. Burris, Daniel ...
Business Profiles
Researchgate: Yohann Loriot
Villejuif, France
Yohann Loriot Institut de Cancérologie Gustave Roussy | IGRwww.researchgate.net › Institut de Cancérologie Gustave Roussy
www.researchgate.net
Yohann LORIOT | Cited by | of Institut de Cancérologie Gustave Roussy, Villejuif (IGR) | Read 414 publications | Contact Yohann LORIOT.
Education
Yohann Loriot, MD, PhD - ReachMDreachmd.com › profiles › yohann-loriot-md-phd › biography
reachmd.com
Yohann Loriot, MD, PhD. Physician Scientist; Director of Bladder Cancer Program; Gustave Roussy; Université Paris-Saclay; Villejuif, France. Biography.
Books & Literature
bol.com: bol.com | Canc�Rologie (ebook), Yohann Loriot | | Boeken
items de cancérologie du programme de DCEM2-DCEM4 (27 items). Chaque ...
Association between lymphoma and melanoma: report of a single ...www.tandfonline.com › ... › List of Issues › Volume 47, Issue 6
www.tandfonline.com
Association between lymphoma and melanoma: report of a single-center series of eight patients and a review of the literature. Yohann Loriot Departments of ...
Canc rologie by Yohann Loriot - Goodreadswww.goodreads.com › book › show › canc-rologie
www.goodreads.com
Yohann Loriot,. Pierre Mordant · Rating details · 0 ratings · 0 reviews. Cet ouvrage de cours synth tique traite l'ensemble des items de canc rologie ...
AACR 2016: Abstracts books.google.co.in › books
books.google.co.in
... Maud Ngocamus,1 Jean Charles Soria,1 Karim Fizazi,1 Yohann Loriot,1 Sylvia Julien,2 Françoise Farace1. 1Institut Gustave Roussy Inserm U981, Villejuif, ...
Related Documents
[PDF] Efficacy of Sacituzumab Govitecan (SG) by Trophoblast Cell Surface ...www.askgileadmedical.com › pdfs › oncology › esmo-2021
www.askgileadmedical.com
21-Sept · Yohann Loriot,1 Arjun V. Balar,2 Daniel P. Petrylak,3 Arash Rezazadeh,4 Petros Grivas,5 Aude Fléchon,6 Rohit K. Jain,7 Neeraj Agarwal,8 ...
[PDF] IMMUNOTHERAPYwww.esmo.org › Immunotherapy-for-Advanced-Bladder-Cancer
www.esmo.org
Yohann Loriot, MD, PhD Q & A Interactive case-based panel discussion Conclusions and prIME Points™. Thomas Powles, MBBS, MRCP, MD.
EORTC abstracts selected at ASCO | EORTC : EORTC
www.eortc.org
Bertrand F. Tombal, Yohann Loriot, Fred Saad, Raymond S. McDermott, Tony Elliott, Alejo Rodriguez Vida, Franco Nole, Beatrice Fournier, ...
Cancérologie - Cahiers des ECN - Critique de David
www.remede.org
Critique du livre Cancérologie - Cahiers des ECN par David
Scientific Publications
Immunotherapies in non-muscle invasive bladder cancer - PubMedpubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
Authors. Yohann Loriot , Morgan Rouprêt. Affiliations. 1 Département de médecine oncologique et INSERM U981, Gustave-Roussy, Cancer Campus, ...
Management of non-metastatic castrate-resistant prostate cancerpubmed.ncbi.nlm.nih.gov › ...
pubmed.ncbi.nlm.nih.gov
Yohann Loriot , Stéphane Supiot , Jean-Baptiste Beauval , Friederike Schlürmann , Gilles Pasticier , Paul Sargos , Philippe Barthélémy , Géraldine Pignot ...
Locoregional symptoms in patients with de novo metastatic prostate...
www.sciencedirect.com
Locoregional symptoms in patients with de novo metastatic prostate cancer: Morbidity, ... Yohann Loriot has received honoraria from Janssen and Sanofi-Aventis and
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et...
pubmed.ncbi.nlm.nih.gov
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma:...
Publications
Create a SciFeed alert for new publications - MDPIwww.mdpi.com › scifeed_display
www.mdpi.com
Yohann Loriot. Andrew J. Armstrong. Karim Fizazi. Tomasz Beer. Cora N. Sternberg. Maha Hussain. Cristina Ivanescu. Arijit Ganguli. Krishnan Ramaswamy.
Yohann Loriot - theses.frwww.theses.fr › ...
www.theses.fr
Sciences de la vie et de la santé. Soutenue le Thèse soutenue. Accéder en ligne. Yohann Loriot a dirigé la thèse suivante : ...
[PDF] Loriot - The role of checkpoint inhibition - Urobelgicaurobelgica.be › wp-content › uploads › › Loriot-The-r...
urobelgica.be
Yohann Loriot, MD, PhD. Département de médecine oncologique, INSERM U981, Villejuif, France . Disclosures – Yohann Loriot.
Publications Authored by Yohann Loriot | PubFacts.com
www.pubfacts.com
Publications Authored By Yohann Loriot Feb. Nonfamilial Chronic Serum Alpha-Fetoprotein Increase in a Patient With Clinical Stage I Seminoma.
Video & Audio
Bladder: enfortumab vedotin + pembrolizumab & VESPER trialwww.youtube.com › watch
www.youtube.com
26-Feb · Yohann Loriot, MD, PhD, Gustave Roussy Institute & University of Paris-Saclay, Paris, France, outlines the key bladder cancer data to ...
Kit-Walkthrough - Prof. Yohann Loriot - 02:00 PM - Vimeovimeo.com › Peer Education › Videos
vimeo.com
04-Oct · This is " Kit-Walkthrough - inExchange - Prof. Yohann Loriot - 02:00 PM - 02:30 PM" by Peer Education on Vimeo, the home for high ...
New emerging treatment options and targeted therapies for bladder ...ecancer.org › video › new-emerging-treatment-options-and-targeted-...
ecancer.org
01-Jun · Dr Arlene Siefker-Radtke (MD Anderson Cancer Center, Houston, USA) and Dr Yohann Loriot (Institut Gustave Roussy, Villejuif, France) discuss ...
Updates on the DANUBE, KEYNOTE-361 and JAVELIN Studieswww.vjoncology.com › Youtube Videos
www.vjoncology.com
23-Sept · Yohann Loriot, MD, PhD, Gustave Roussy Institute, Villejuif, France, summarises the key finding of the trials DANUBE (NCT ), ...
Reports & Statements
Erratum: Drug Insight: gastrointestinal and hepatic adverse effects of ...www.nature.com › nature reviews clinical oncology › corrigenda
www.nature.com
Erratum: Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Yohann Loriot ,; Gabriel Perlemuter ...
Yohann Loriot - the ome-forumwww.ome-forum.com › ome › presenter › yohann-loriot
www.ome-forum.com
Yohann Loriot is a medical oncologist at the Gustave Roussy Cancer Institute Cancer Campus of the Université Paris-Saclay in the Villejuif commune of Paris, ...
Pemetrexed-Induced Pneumonitis: A Case Report - Clinical Lung ...www.clinical-lung-cancer.com › article › references
www.clinical-lung-cancer.com
Yohann Loriot. Yohann Loriot. Affiliations. Department of Medicine, SITEP, Institut Gustave Roussy, Universite Paris XI, Marie Curie, Paris VI.
nature.com search
www.nature.com
Drug Insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy · Yohann Loriot; , Gabriel Perlemuter; , David Malka ...
Miscellaneous
Auteur - Dr Yohann LORIOT - Edimarkwww.edimark.fr › yohann-loriot-2
www.edimark.fr
Dr Yohann LORIOT Médecin Oncologie Gustave-Roussy Cancer Campus – Grand Paris, Villejuif France. Département d'oncologie médicale, Gustave-Roussy Cancer ...
Expert Point of View: Yohann Loriot, MD, PhD - The ASCO Postascopost.com › issues › october › expert-point-of-view-yohann-l...
ascopost.com
25-Oct · FORMAL DISCUSSANT of the RANGE trial at the ESMO Congress, Yohann Loriot, MD, PhD, of the Institut Gustave Roussy and University of ...
Yohann LORIOT - Focus Meetingwww.focus-meeting.fr › Speakers
www.focus-meeting.fr
Yohann LORIOT. Onco-Urologue, Institut Gustave Roussy. Dr Yohann LORIOT. Yohann LORIOT ... Biography. All sessions by Yohann LORIOT ...
Yohann Loriot - El Corte Ingléswww.elcorteingles.es › bio › yohann-loriot
www.elcorteingles.es
Si te gusta Yohann Loriot, consulta su biografía en El Corte Inglés. Descubre más artistas como Yohann Loriot y compra su obra online al mejor precio.
Yohann Loriot | LinkedIn
www.linkedin.com
View Yohann Loriot's professional profile on LinkedIn. LinkedIn is the world's largest business network, helping professionals like Yohann Loriot discover inside ...
Yohann Loriot | Publonspublons.com › researcher › yohann-loriot
publons.com
View Yohann Loriot's profile on Publons with 457 publications.
Yohann Loriot | Videos & Research | VJOncologywww.vjoncology.com › speaker › yohann-loriot
www.vjoncology.com
Yohann Loriot speaks exclusively to VJOncology, The Video Journal of Oncology. Watch interviews and discussions with Yohann Loriot here.
Dr Yohann LORIOT - Orphanetwww.orpha.net › consor › cgi-bin › Directory_Professionals › title=Dr-Yo...
www.orpha.net
Dr Yohann LORIOT · Equipe Radiothérapie moléculaire · UMR · CLCC Institut Gustave Roussy · 114 rue Edouard Vaillant · VILLEJUIF CEDEX · FRANCE · More ...
Oncologue médical Dr YOHANN LORIOT à , Villejuif - Maiiawww.maiia.com › oncologue-medical › loriot-yohann
www.maiia.com
Prenez RDV en ligne avec Dr YOHANN LORIOT, Oncologue médical au 39 B Rue CAMILLE DESMOULINS pour vous ou vos proches à son cabinet.
Researcher: Yohann Loriot in Publications - Dimensions appapp.dimensions.ai › discover › publication
app.dimensions.ai
Sumanta K Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L Maughan, Yohann Loriot, ...
ADC Continues to Show Clinical Activity in Heavily Pretreated ...www.cancernetwork.com › view › adc-continues-to-show-clinical-activity-i...
www.cancernetwork.com
20-Sept · ... platinum-based chemotherapy and checkpoint inhibitors,” Yohann Loriot, MD, PhD, lead author of the study and a medical oncologist at the ...
ASCO GU | Further JAVELIN Bladder 100 analyses add ...oncology.medicinematters.com › javelin-bladder-100-maintenance-avelumab
oncology.medicinematters.com
18-Feb · ... posters at the Genitourinary Cancers Symposium, the first set by Yohann Loriot (Gustave Roussy, Villejuif, France) and colleagues, ...
ASCO GU 2021: Avelumab First-Line Maintenance Plus Best ...www.urotoday.com › asco-gu › bladder-cancer › asco-gu-2...
www.urotoday.com
14-Feb · Yohann Loriot and colleagues presented results of their post hoc analysis of the JAVELIN Bladder 100 trial, specifically efficacy by duration or ...
Abstract 4891: Radiation enhances the efficacy of Bcl-2 and Bcl-X L ...dx.doi.org › ...
dx.doi.org
04-Apr · Yohann Loriot ; Pierre Mordant ; Delphine Dugué ; Andrea Gombos ; Paule Opolon ...
Cancer de la vessie - Equipe | Gustave Roussywww.gustaveroussy.fr › cancer-de-la-vessie-equipe
www.gustaveroussy.fr
Dr Yohann Loriot. Oncologie médicale. Pr Karim Fizazi Dr Laurence Albiges Dr Bernard Escudier Dr Yohann Loriot Dr Giulia Baciarello Dr Alina Fuerea
De-escalating Chemotherapy Possible in Low-Risk Patients with ...theoncologypharmacist.com › issues › may vol-13-no-3 ›
theoncologypharmacist.com
21-May · “De-escalating chemotherapy based on early FDG-PET is safe and feasible in metastatic seminoma,” said Yohann Loriot, MD, PhD, Oncologist, ...
Faculty | BMUCbmuc.be › bmuc2020 › faculty
bmuc.be
Yohann Loriot. Department of Cancer Medicine. Institut Gustave Roussy Paris, France. Tim Muilwijk. Department of Urology. University Hospitals Leuven
High-throughput genomics and clinical outcome in hard-to-treat ...mdanderson.elsevierpure.com › publications › high-throughput-genomics-...
mdanderson.elsevierpure.com
... Rastislav Bahleda, Anas Gazzah, Andrea Varga, Sophie Postel-Vinay, Yohann Loriot, Caroline Even, Ingrid Breuskin, Nathalie Auger, Bastien Job
Inhibition of BCL-2 in Small Cell Lung Cancer Cell Lines with ...ar.iiarjournals.org › content
ar.iiarjournals.org
YOHANN LORIOT, PIERRE MORDANT, BOB D. BROWN, JEAN BOURHIS, JEAN-CHARLES SORIA and ERIC DEUTSCH. Anticancer Research October 2010, 30 (10) ;.
One Size Does Not Fit All: Can We Choose the Best Sequence of ...www.europeanurology.com › article › fulltext
www.europeanurology.com
One Size Does Not Fit All: Can We Choose the Best Sequence of Treatment in Asymptomatic Castration-resistant Prostate Cancer Patients? Yohann Loriot.
Related search requests for Yohann Loriot
| Andrea Necchi Pierre Mordant Karim Fizazi | Laurence Albiges Thomas Powles Robert Huddart |
People Forename "Yohann" (614) Name "Loriot" (92) |
sorted by relevance / date